BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15577584)

  • 1. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake.
    Rosário PW; Reis JS; Barroso AL; Rezende LL; Padrão EL; Fagundes TA
    Nucl Med Commun; 2004 Nov; 25(11):1077-81. PubMed ID: 15577584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma.
    Rosário PW; Maia FF; Cardoso LD; Barroso A; Rezende L; Padrão EL; Purisch S
    Clin Nucl Med; 2004 Jun; 29(6):358-61. PubMed ID: 15166882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
    Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
    Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased uptake after fractionated ablative doses of iodine-131.
    Wu HS; Hseu HH; Lin WY; Wang SJ; Liu YC
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):167-73. PubMed ID: 15351912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
    Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
    Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
    Hodgson DC; Brierley JD; Tsang RW; Panzarella T
    Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
    Rubello D; Mazzarotto R; Casara D
    Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer.
    Rosário PW; Barroso AL; Rezende LL; Padrão EL; Fagundes TA; Reis JS; Purisch S
    Ann Nucl Med; 2005 May; 19(3):247-50. PubMed ID: 15981681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy.
    de Klerk JM; de Keizer B; Zelissen PM; Lips CM; Koppeschaar HP
    Nucl Med Commun; 2000 Jun; 21(6):529-32. PubMed ID: 10894561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
    Silberstein EB
    J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I.
    Verburg FA; Verkooijen RB; Stokkel MP; van Isselt JW
    Nuklearmedizin; 2009; 48(4):138-42; quiz N19-20. PubMed ID: 19384451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
    J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
    Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
    Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
    Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.